Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.

@article{Jnne2022AdagrasibIN,
  title={Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.},
  author={Pasi A. J{\"a}nne and Gregory Riely and Shirish M. Gadgeel and Rebecca S. Heist and S-H.I. Ou and Jose Maria Pacheco and Melissa L. Johnson and Joshua K. Sabari and Konstantinos Leventakos and Edwin Yau and Lyudmila Bazhenova and Marcelo Vailati Negr{\~a}o and Nathan A. Pennell and Jun Zhang and Kenna Anderes and Hirak Der-Torossian and Thian San Kheoh and Karen Velastegui and Xiao Qiang Yan and James G. Christensen and Richard C. Chao and Alexander I. Spira},
  journal={The New England journal of medicine},
  year={2022}
}
BACKGROUND Adagrasib, a KRASG12C inhibitor, irreversibly and selectively binds KRASG12C, locking it in its inactive state. Adagrasib showed clinical activity and had an acceptable adverse-event profile in the phase 1-1b part of the KRYSTAL-1 phase 1-2 study. METHODS In a registrational phase 2 cohort, we evaluated adagrasib (600 mg orally twice daily) in patients with KRASG12C -mutated non-small-cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy and anti-programmed… 

Adagrasib: A landmark in the KRASG12C‐mutated NSCLC

Adagrasib showed encouraging efficacy and acceptable safety, offering novel therapeutic avenues for KRASG12C-mutated NSCLC, which had accepted treatment with at least one platinum-based chemotherapy regimen and immune checkpoint inhibitors (ICIs) therapy.

The KRYSTAL-1 study of adagrasib — a new trial for KRASG12C-mutated non-small-cell lung cancer

Recent data from the phase II KRYSTAL-1 trial of adagrasib in KRASG12C-mutated non-small-cell lung cancer (NSCLC) showed responses in a subset of patients, including among those with brain metastases, and offers exploratory insights into potential biomarkers of response.

KRAS in NSCLC: State of the Art and Future Perspectives

The efficacy of immune-checkpoint inhibitors still needs to be completely assessed and responses to anti-PD-1/PD-L1 agents may strongly depend on concomitant mutations, but ongoing trials and future needs for this subpopulation cohort are overviewed.

A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib

The mechanism of action, pharmacokinetic and pharmacodynamic properties, efficacy, and tolerability of adagrasib (MRTX849) are discussed.

KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges

The aim of this review was to analyze the state-of-the-art of KRAS mutations in non-small-cell lung cancer by describing the biological structure ofKRAS and exploring the clinical relevance of KRas as a prognostic and predictive biomarker, and reviewing the different treatment approaches.

A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice

Subgroup analysis revealed the benefits of immunotherapy compared to chemotherapy were applicable in PD-L1 expression≥1% subgroup, and antiangiogenic therapy could benefit non-G12C KRAS sub group, but not G12CKRAS subgroup; and platinum-pemetrexed combined with antiangIogenic therapy may be the preferred chemotherapy regimen.

Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?

In some cases, the therapy is efficient, and more research is required to establish the management of NSCLC patients with oncogenic driver abnormalities, as current discoveries in immunotherapy with immune checkpoint inhibitors are reviewed.

KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic Strategy, and Potential Treatment Exploration

The characteristics of KRAS mutations in cancer patients, and the prognostic effect that it poses on different therapies and advanced therapeutic strategy are reviewed, as well as cutting-edge research on the mechanisms of drug resistance, tumor development, andThe immune microenvironment are reviewed.

Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in KRAS Mutant Non-Small Cell Lung Cancer Cell Lines

Evaluating the efficacy of pan-EGFR inhibitors in a panel of 15 lung cancer cell lines associated with the KRAS mutations phenotype indicated that allitinib was more effective than afatinib in NSCLC cell lines.

References

SHOWING 1-10 OF 14 REFERENCES

Targeting KRAS in non-small cell lung cancer: recent progress and new approaches.

Clinical and Imaging Features of Non-Small Cell Lung Cancer with G12C KRAS Mutation

It is found that KRAS G12C NSCLC has distinct primary tumor imaging features and patterns of metastasis when compared to those ofNSCLC driven by other genetic alterations.

Personalized therapy for lung cancer: striking a moving target.

This review focuses on recent advances in targeted therapy, mechanisms of resistance, and therapeutic strategies to overcome resistance in patients with lung cancer.

Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition

This study uncovers a flexible non-uniform fitness mechanism that enables groups of cells within a population to rapidly bypass the effect of treatment and must be overcome if complete and durable responses in the clinic.

Mechanisms of Resistance to KRASG12C Inhibitors

The current evidence for G12C inhibitors, the mechanisms of resistance to G 12C inhibitors and potential approaches to overcome them are discussed, including possible targets of combination therapy, including SHP2, receptor tyrosine kinases, downstream effectors and PD1/PDL1.

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

Findings reveal that KRASG12C undergoes nucleotide cycling in cancer cells and provide a basis for developing effective therapies to treat KRASg12C-driven cancers.

Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.

The discovery of the clinical development candidate MRTX849 as a potent, selective covalent inhibitor of KRASG12C is described.